<div id="readability-page-1"><div>Graf Finckenstein Friedrich Officer of Iovance Biotherapeutics Inc [IOVA] filed a Form 4 on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>12/1/25-12/2/25</td><td>Exercise</td><td>12,695</td><td>$0.00</td><td>N/A</td></tr><tr><td>12/1/25-12/2/25</td><td>Surrender(1)</td><td>6,448</td><td>$2.20</td><td>$14,200</td></tr></tbody></table></div>Ending Holdings: 111,656 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

IOVA

Graf Finckenstein, an officer of Iovance Biotherapeutics Inc, filed a Form 4 with the SEC on December 3, 2025, disclosing changes in ownership. He exercised 12,695 shares and surrendered 6,448 shares at $2.20 each to cover option exercise costs and tax liabilities. His ending holdings are 111,656 shares. This transaction highlights insider trading activities within the company.

Officer Graf Finckenstein Acquires 6,247 Of Iovance Biotherapeutics Inc [IOVA]